ITCIIntra-Cellular Therapies Inc

$0.00
$0.00
(0.00%)
Today
Updated:
Reported EarningsFeb 21
Mkt Cap$14.05B
Vol16.06M
News
all
press releases
News Placeholder
Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus
March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs boosted sentiment, while investors awaited crucial producer inflation data and comments from Federal Reserve officials.
barchart.com
News Placeholder
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.
Stocktwits
News Placeholder
J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports
investing.com
<
...
1
>

Advertisement|Remove ads.